


## Sample Screenshots of Antibody Database July 4, 2013



La Merie - Mozilla Firefox

File Edit View History Bookmarks Tools Help

db.pipelinereview.com/projects

La Merie

**La:Merie**  
Business Intelligence

Dear WalFix,  
Your account will expire on **December 31, 2013**.  
If you encounter any problems or have questions, please contact us at support@pipelinereview.com

LOGOUT SEARCH EXPORT REPORTS **PROJECTS**

**Projects** Print

| Id    | Last Update | Project                                    | Target                                                    | Class of Compound                        | Category | Company                                      | Territory             | Therapeutic Area        | Indication                                                 | Phase        |  |
|-------|-------------|--------------------------------------------|-----------------------------------------------------------|------------------------------------------|----------|----------------------------------------------|-----------------------|-------------------------|------------------------------------------------------------|--------------|--|
| 18840 | 2013-07-03  | REGN728; REGN-728                          | Not disclosed                                             | Rec fully human monoclonal antibody      | Antibody | Regeneron Pharmaceuticals                    | France, United States | Rheumatoid & autoimmune | Not disclosed                                              | Discontinued |  |
| 18839 | 2013-07-03  | MDX-070                                    | Prostate specific membrane antigen (PSMA)                 | Rec fully human IgG1 monoclonal antibody | Antibody | Bristol-Myers Squibb (BMS, acquired Medarex) | United States         | Oncology                | Prostate cancer                                            | Discontinued |  |
| 18838 | 2013-07-03  | Robatumumab; SCH-717454; 19D12             | Insulin-like growth factor 1 receptor (IGF-1R) antagonist | Rec fully human IgG1 monoclonal antibody | Antibody | Merck (acquired Schering-Plough)             | United States         | Oncology                | Cancer                                                     | Discontinued |  |
| 18837 | 2013-07-03  | ABX-MA1                                    | MUC18 (CD146)                                             | Rec fully human IgG2 mab (XenoMouse)     | Antibody | Amgen (acquired Abgenix)                     | United States         | Oncology                | Melanoma                                                   | Discontinued |  |
| 18836 | 2013-07-03  | ABX-IL8                                    | Interleukin-8 (IL-8)                                      | Rec fully human IgG2 mab (XenoMouse)     | Antibody | Amgen (acquired Abgenix)                     | United States         | Rheumatoid & autoimmune | Inflammatory diseases                                      | Discontinued |  |
| 18835 | 2013-07-03  | ABX-325; A-794722                          | Interleukin-18 (IL-18)                                    | Rec fully human IgG1 mab (XenoMouse)     | Antibody | Abbott (AbbVie)                              | United States         | Rheumatoid & autoimmune | Inflammatory diseases                                      | Discontinued |  |
| 18834 | 2013-07-03  | ABX-10241; ABX-PTH                         | Parathyroid hormone (PTH)                                 | Rec fully human IgG2 mab (XenoMouse)     | Antibody | Amgen (acquired Abgenix)                     | United States         | Metabolism & endocrine  | Secondary hyperparathyroidism                              | Discontinued |  |
| 18833 | 2013-07-03  | Perjeta (US); Omnitarg; pertuzumab; RG1273 | HER2 dimerization                                         | Rec humanized IgG1 mab                   | Antibody | Roche & Genentech                            |                       | Oncology                | Before surgery (neoadjuvant treatment) in people with sR/A |              |  |

Find: 421 Next Previous Highlight all Match case Reached end of page, continued from top

ES 10:55 04/07/2013



La Merie - Mozilla Firefox

File Edit View History Bookmarks Tools Help

db.pipelinereview.com/projects/search

La Merie

**La:Merie**  
Business Intelligence

Dear WalFix,  
Your account will expire on December 31, 2013.  
If you encounter any problems or have questions, please contact us at support@pipelinereview.com

LOGOUT SEARCH EXPORT REPORTS PROJECTS

**Search**

Search Clear

☐ Any Word ☐ All Words ☐ Exact Phrase ☒ Advanced Search

Target: All Targets

Technology: All Technologies

**Territory**

- All Countries
- Aaland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

**Therapeutic Area**

- All Therapeutic Areas
- Cardiovascular, blood & acute care
- Dermatology

**Phase**

- All Phases
- Market
- sBLA

| Id    | Last Update | Project                                       | Target                                                                                                         | Class of Compound                                                                               | Category | Company                    | Territory          | Therapeutic Area                   | Indication                         | Phase    |  |
|-------|-------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------|----------------------------|--------------------|------------------------------------|------------------------------------|----------|--|
| 18518 | 2013-04-18  | Factor VIIInexP; Factor VII/IgG-Fc (Alteogen) | Coagulation factor VII receptor agonist                                                                        | Rec fusion protein of F.VII with N-terminal amino acid Ala and Fc of IgG expressed in CHO cells | Antibody | Alteogen                   | Korea, Republic of | Cardiovascular, blood & acute care | Hemophilia A and B with inhibitors | Research |  |
| 18397 | 2013-03-20  | Sotatercept; ACE-011                          | Blocks signaling through ActRIIA: increases erythrocyte levels by targeting molecules in the TGF-β superfamily | Rhu dimeric fusion protein of ED of activin receptor-2a (ActRIIA) and Fc of IgG1                | Antibody | Accelaron Pharma & Celgene | United States      | Cardiovascular, blood & acute care | Beta Thalassemia                   | II       |  |
| 18169 | 2012-12-07  | NKTT120; NKTT-120                             | Depletion of invariant natural killer cells (iNKT)                                                             | Rec humanized monoclonal antibody                                                               | Antibody | NKTT Therapeutics          | United States      | Cardiovascular, blood & acute care | Sickle cell disease                | 0        |  |

Rec humanized (hybrid Complement C5

Find: 421

Next Previous Highlight all Match case Reached end of page, continued from top

ES 10:57 04/07/2013

La Merie - Mozilla Firefox

File Edit View History Bookmarks Tools Help

db.pipelinerreview.com/projects/search

La Merie

Search Clear

Any Word All Words Exact Phrase ☒ Advanced Search

Target: All Targets

Technology: All Technologies

Therapeutic Area

All Therapeutic Areas  
Cardiovascular, blood & acute care  
Dermatology

| Id    | Last Update | Project                                     | Target                                                                                                     |
|-------|-------------|---------------------------------------------|------------------------------------------------------------------------------------------------------------|
| 18518 | 2013-04-18  | Factor VIIINexP; Factor VIIIG-Fc (Alteogen) | Coagulation receptor as                                                                                    |
| 18397 | 2013-03-20  | Sotatercept; ACE-011                        | Blocks sign through Act increases erythrocyte targeting m in the TGF- $\beta$ superfamily                  |
| 18169 | 2012-12-07  | NKTT120; NKTT-120                           | Depletion of natural killer (NKT)                                                                          |
| 18022 | 2013-03-15  | Eculizumab biosimilar (BioXpress)           | Complement antagonist, formation of                                                                        |
| 17764 | 2013-02-08  | ACE910; ACE-910                             | Mimics function of FVIII by simultaneous binding factor and factor promote factor Xa-mediated X activation |
| 17573 | 2012-08-04  | IAb-X43                                     | Vascular target                                                                                            |

### View Project [18169]

[Print](#)

**Last Update:** 2012-12-07

**NKTT120; NKTT-120**

**Target:** Depletion of invariant natural killer cells (NKT)

**Class of Compound:** Rec humanized monoclonal antibody

**Category:** Antibody

**Company:** NKTT Therapeutics

**Territory:** United States

**Therapeutic Area:** Cardiovascular, blood & acute care

**Indication:** Sickle cell disease

**Phase:** 0

**Administration:**

**Drug Delivery:**

**Status:** Active

**Approval US:**

**Approval UE:**

**Approval RoW:**

**Antibody Tech:**

**Protein Tech:**

**DNA Tech:**

**RNA Tech:**

**Cell Tech:**

**Vaccine Tech:**

**Partnering**

**News**

| Date       | Title                                           | Comments                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|------------|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2012-12-07 | <a href="#">NKT Therapeutics PR Dec 6, 2012</a> | Preclinical studies of NKTT120, a humanized monoclonal antibody, showed its ability to generate a safe, rapid, specific and complete depletion of invariant Natural Killer T cells (NKT cells) 24 hours post dosing, thus offering a means to reduce the chronic inflammation associated with sickle cell disease pathology. NKT Therapeutics plans to initiate a clinical trial of NKTT120 in patients with stable sickle cell disease in the first quarter of 2013. |

| Indication                                | Phase       |  |
|-------------------------------------------|-------------|--|
| Hemophilia A and B with inhibitors        | Research    |  |
| Beta Thalassemia                          | II          |  |
| Sickle cell disease                       | 0           |  |
| Atypical hemolytic uremic syndrome (aHUS) | Research    |  |
| Hemophilia A                              | I           |  |
| Cardiovascular disorder                   | Preclinical |  |

Find: 421

Next Previous Highlight all Match case Reached end of page, continued from top

ES 10:58 04/07/2013

La Merie - Mozilla Firefox

File Edit View History Bookmarks Tools Help

db.pipelinereview.com/projects/search

La Merie

**LaMerie**  
Business Intelligence

Dear WalFix,  
Your account will expire on **December 31, 2013**.  
If you encounter any problems or have questions, please contact us at support@pipelinereview.com

LOGOUT SEARCH EXPORT REPORTS PROJECTS

**Search**

Print Export Export

Search Clear

☐ Any Word ☐ All Words ☐ Exact Phrase ☒ Advanced Search

Target: All Targets

Techno

**Id**

**Territory**

**Therapeutic Area**

**Phase**

| Id | Category | Company | Territory | Therapeutic Area | Indication | Phase |
|----|----------|---------|-----------|------------------|------------|-------|
|----|----------|---------|-----------|------------------|------------|-------|

Projects 0 to 0 of 0

Find: 421

Next Previous Highlight all Match case Reached end of page, continued from top

ES 11:00 04/07/2013



La Merie - Mozilla Firefox

File Edit View History Bookmarks Tools Help

db.pipelinereview.com/projects/search

La Merie

**LaMerie**  
Business Intelligence

Dear WalFix,  
Your account will expire on **December 31, 2013**.  
If you encounter any problems or have questions, please contact us at [support@pipelinereview.com](mailto:support@pipelinereview.com)

LOGOUT SEARCH EXPORT REPORTS PROJECTS

**Search**

Search Clear

☐ Any Word ☐ All Words ☐ Exact Phrase ☒ Advanced Search

Target: BlyS, BAFF & APRIL Antagonists

Technology: All Technologies

**Territory**

- All Countries
- Aaland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

**Therapeutic Area**

- All Therapeutic Areas
- Cardiovascular, blood & acute care
- Dermatology

**Phase**

- All Phases
- Market
- sBLA

Print Export Export

| Id    | Last Update | Project                           | Target                                   | Class of Compound                                                                                                       | Category | Company                                                    | Territory     | Therapeutic Area                  | Indication                                                        | Phase |  |
|-------|-------------|-----------------------------------|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|----------|------------------------------------------------------------|---------------|-----------------------------------|-------------------------------------------------------------------|-------|--|
| 18791 | 2013-06-25  | Blisibimod; A-623                 | Broad inhibitor of BAFF                  | Peptibody: rec fusion protein of novel BAFF binding domain fused to the N-terminus of the Fc region of Ig for SC design | Antibody | Anthera Pharmaceuticals (from Amgen)                       | United States | Genitourinary, renal & gynecology | IgA nephropathy                                                   | Ia    |  |
| 17362 | 2013-07-01  | VAY736; VAY-736                   | BAFF-R                                   | Rec fully human mab (HuCAL)                                                                                             | Antibody | Novartis (from MorphoSys)                                  | Switzerland   | Oncology                          | Chronic lymphocytic leukemia                                      | I     |  |
| 16896 | 2013-07-01  | Benlysta; belimumab; LymphoStat-B | B-lymphocyte stimulator (BLyS) inhibitor | Rec fully human IgG1 mab (from phage display)                                                                           | Antibody | GlaxoSmithKline (GSK, acquired Human Genome Sciences, HGS) | United States | Rheumatoid & autoimmune           | ANCA (Anti-neutrophil Cytoplasmic Antibodies) positive vasculitis | III   |  |

Peptibody: rec fusion

Find: 421

Next Previous Highlight all Match case Reached end of page, continued from top

ES 11:01 04/07/2013

La Merie - Mozilla Firefox

File Edit View History Bookmarks Tools Help

db.pipelinereview.com/projects/search

Google

La Merie

+

LaMerie

Business Intelligence

Dear WalFix,

Your account will expire on **December 31, 2013.**

If you encounter any problems or have questions, please contact us at [support@pipelinereview.com](mailto:support@pipelinereview.com)

LOGOUT

SEARCH

EXPORT REPORTS

PROJECTS

Search

Print

Export

Export

Search

Clear

☐ Any Word
 ☐ All Words
 ☐ Exact Phrase
 ☒ Advanced Search

Target: All Targets

Technology: All Technologies

Id

Last

ADC - Auristatin

ADC - Calicheamicin

ADC - Doxorubicin

ADC - Duocarmycin

ADC - Maytansinoid

ADC - Others

ADC - Proteins & Peptides

ADC - Pyrrolbenzodiazepine (PBD)

ADC - SN-38 (irinotecan metabolite)

Agonist Antibodies

Bispecific Antibodies

Bispecific Proteins

Camelid-derived Domain Antibodies

Deimmunized Antibodies

Human Cell-derived Antibodies

Human Engineered Antibodies (XOMA technology)

Humaneered Antibodies (KaloBios)

In vitro: Phage Display (scFv/Fab library) Antibodies

Oligo- and Polyclonal Antibodies

Territory

All Countries

Aaland Islands

Afghanistan

Albania

Algeria

American Samoa

Andorra

Angola

Therapeutic Area

All Therapeutic Areas

Cardiovascular, blood & acute care

Dermatology

Phase

All Phases

Market

sBLA

| Compound             | Category | Company | Territory | Therapeutic Area | Indication | Phase |
|----------------------|----------|---------|-----------|------------------|------------|-------|
| Projects 0 to 0 of 0 |          |         |           |                  |            |       |

Find: 421

Next Previous Highlight all Match case Reached end of page, continued from top

ES

11:02

04/07/2013



La Merie - Mozilla Firefox

File Edit View History Bookmarks Tools Help

db.pipelinereview.com/projects/search

La Merie

**La Merie**  
Business Intelligence

Dear WalFix,  
Your account will expire on **December 31, 2013**.  
If you encounter any problems or have questions, please contact us at [support@pipelinereview.com](mailto:support@pipelinereview.com)

LOGOUT SEARCH EXPORT REPORTS PROJECTS

**Search**

Search Clear

☐ Any Word ☐ All Words ☐ Exact Phrase ☒ Advanced Search

Target: All Targets

Technology: ADC - Maytansinoid

**Territory**

- All Countries
- Aaland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

**Therapeutic Area**

- All Therapeutic Areas
- Cardiovascular, blood & acute care
- Dermatology

**Phase**

- All Phases
- Market
- sBLA

**Print** **Export** **Export**

| Id    | Last Update | Project                                                           | Target            | Class of Compound                                                       | Category | Company                                       | Territory          | Therapeutic Area | Indication                                                                     | Phase       |  |
|-------|-------------|-------------------------------------------------------------------|-------------------|-------------------------------------------------------------------------|----------|-----------------------------------------------|--------------------|------------------|--------------------------------------------------------------------------------|-------------|--|
| 18508 | 2013-04-13  | Antibody-Drug Conjugate (ADC) (Novartis)                          | N/D               | Rhu mab with Targeted Antibody Payload (TAP)                            | Antibody | Novartis (with TAP technology from ImmunoGen) | Switzerland        | Oncology         | Cancer                                                                         | Preclinical |  |
| 18507 | 2013-04-13  | SAR-3419; SAR3419; huB4-DM4; Maytansin-loaded anti-CD19 mAb       | CD19 and payload  | Rec humanized IgG1 mab conjugated with maytansinoid DM4 via SPDB linker | Antibody | Sanofi (mab and technology from ImmunoGen)    |                    | Oncology         | Acute lymphoblastic leukemia                                                   | II          |  |
| 18506 | 2013-04-13  | SAR-3419; SAR3419; huB4-DM4; Maytansin-loaded anti-CD19 mAb       | CD19 and payload  | Rec humanized IgG1 mab conjugated with maytansinoid DM4 via SPDB linker | Antibody | Sanofi (mab and technology from ImmunoGen)    |                    | Oncology         | Diffuse large B-cell lymphoma (DLBCL). Non-Hodgkin's lymphoma - with rituximab | II          |  |
| 18505 | 2013-04-13  | Kadcyla; ado-trastuzumab emtansine; trastuzumab-HER2 plus payload | HER2 plus payload | Rec humanized IgG1 mab conjugated with                                  | Antibody | Roche (Genentech) (technology from            | Switzerland,United | Oncology         | HER2-positive advanced                                                         | sBLA        |  |

Find: 421

Next Previous Highlight all Match case Reached end of page, continued from top

ES 11:02 04/07/2013

La Merie - Mozilla Firefox

File Edit View History Bookmarks Tools Help

db.pipelinereview.com/projects/reports

La Merie

**La:Merie**  
Business Intelligence

Dear WalFix,  
Your account will expire on **December 31, 2013**.  
If you encounter any problems or have questions, please contact us at support@pipelinereview.com

LOGOUT SEARCH **EXPORT REPORTS** PROJECTS

**Export Reports** Print Export Export

Date:  to:  Custom Report Search Clear

**Territory**

- All Countries
- Aaland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

**Target:**

All Targets

**Keyword**

Humanized

☒ Any Word ☐ All Words ☐ Exact Phrase

**Technology:**

All Technologies

**Therapeutic Area**

- All Areas
- Cardiovascular, blood & acute care
- Dermatology

**Phase**

- All Phases
- Market
- sBLA

| Id | Project                             | Target                                              | Class of Compound                                  | Company                      | Category | Indication                                                         | R&D Stage | Message |
|----|-------------------------------------|-----------------------------------------------------|----------------------------------------------------|------------------------------|----------|--------------------------------------------------------------------|-----------|---------|
| 37 | Soliris; eculizumab; H5G1.1         | Complement C5 antagonist, reducing formation of C5a | Rec humanized (hybrid IgG2/4) Fc-modified full mab | Alexion Pharmaceuticals      | Antibody | Paroxysmal nocturnal hemoglobinuria (PNH)                          | Market    |         |
| 90 | Xolair; omalizumab; RG3648; RG-3648 | IgE                                                 | Rec humanized IgG1 mab                             | Roche (Genentech) & Novartis | Antibody | Severe allergic asthma in adults and adolescents (age 12 or above) | Market    |         |

Find: 421 Next Previous Highlight all ☒ Match case Reached end of page, continued from top

ES 11:04 04/07/2013

La Merie - Mozilla Firefox

db.pipelinereview.com/projects/reports

La Merie

Dear WalFix,  
Your account will expire on December 31, 2013.  
If you encounter any problems or have questions, please contact us at support@pipelinereview.com

LOGOUT SEARCH EXPORT REPORTS PROJECTS

### Export Reports

Date:  to:  Custom Report

**Territory**

- All Countries
- Aaland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

**Target:**

All Targets

**Technology:**

All Technologies

**Keyword**

Humanized

☒ Any Word ☐ All Words ☐ Exact Phrase

**Therapeutic Area**

- All Areas
- Cardiovascular, blood & acute care
- Dermatology

**Phase**

- All Phases
- Market
- sBLA

| Id | Project                             | Target                                              | Class of Compound                                  | Company                      | Category | Indication                                                         |
|----|-------------------------------------|-----------------------------------------------------|----------------------------------------------------|------------------------------|----------|--------------------------------------------------------------------|
| 37 | Soliris; eculizumab; H5G1.1         | Complement C5 antagonist, reducing formation of C5a | Rec humanized (hybrid IgG2/4) Fc-modified full mab | Alexion Pharmaceuticals      | Antibody | Paroxysmal hemoglobinuria                                          |
| 90 | Xolair; omalizumab; RG3648; RG-3648 | IgE                                                 | Rec humanized IgG1 mab                             | Roche (Genentech) & Novartis | Antibody | Severe allergic asthma in adults and adolescents (age 12 or above) |

Find: 421    ☒ Match case

Opening projects.xlsx

You have chosen to open:

**projects.xlsx**

which is a: Documento de Microsoft Word 97-2003  
from: http://db.pipelinereview.com

What should Firefox do with this file?

☒ Open with

☐ Save File

☐ Do this automatically for files like this from now on.

ES 11:05 04/07/2013